Ascentage Pharma Group Inc.

Biopharmaceutical company developing targeted cancer therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New pill shows promise for tough blood cancers Results expected Dec 2026 (estimated)
• New combo therapy aims to outsmart resistant blood cancer Results expected Dec 2026 (estimated) 🚀 Make-or-break
• Can a targeted pill shrink a rare, Treatment-Resistant stomach cancer? Results expected Mar 2027 (estimated)
• Experimental pill takes on Hard-to-Treat ovarian cancer Results expected May 2027 (estimated)
• Can a drug duo outsmart resistant tumors? Results expected Jun 2027 (estimated)